Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Identifieur interne : 002927 ( Main/Exploration ); précédent : 002926; suivant : 002928Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Auteurs : Janaki Amin [Australie] ; Mark A. Boyd [Australie] ; Nagalingeswaran Kumarasamy [Inde] ; Cecilia L. Moore [Australie] ; Marcello H. Losso [Argentine] ; Chidi A. Nwizu [États-Unis] ; Lerato Mohapi [Afrique du Sud] ; Stephen J. Kerr [Thaïlande] ; Annette H. Sohn [Thaïlande] ; Hedy Teppler [États-Unis] ; Boris Renjifo [États-Unis] ; Jean-Michel Molina [France] ; Sean Emery [Australie] ; David A. Cooper [Australie]Source :
- PLoS ONE [ 1932-6203 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Association de médicaments, Humains, Infections à VIH (traitement médicamenteux), Inhibiteurs de l'intégrase du VIH (administration et posologie), Inhibiteurs de l'intégrase du VIH (effets indésirables), Inhibiteurs de l'intégrase du VIH (usage thérapeutique), Inhibiteurs de protéase du VIH (administration et posologie), Inhibiteurs de protéase du VIH (effets indésirables), Inhibiteurs de protéase du VIH (usage thérapeutique), Lopinavir (administration et posologie), Lopinavir (effets indésirables), Lopinavir (usage thérapeutique), Mâle, Raltégravir de potassium (administration et posologie), Raltégravir de potassium (effets indésirables), Raltégravir de potassium (usage thérapeutique), Ritonavir (administration et posologie), Ritonavir (effets indésirables), Ritonavir (usage thérapeutique), Soins secondaires, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- MESH :
- administration et posologie : Inhibiteurs de l'intégrase du VIH, Inhibiteurs de protéase du VIH, Lopinavir, Raltégravir de potassium, Ritonavir.
- effets indésirables : Inhibiteurs de l'intégrase du VIH, Inhibiteurs de protéase du VIH, Lopinavir, Raltégravir de potassium, Ritonavir.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Inhibiteurs de l'intégrase du VIH, Inhibiteurs de protéase du VIH, Lopinavir, Raltégravir de potassium, Ritonavir.
- Adulte, Association de médicaments, Humains, Mâle, Soins secondaires, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Adult, Drug Therapy, Combination, HIV Infections (drug therapy), HIV Integrase Inhibitors (administration & dosage), HIV Integrase Inhibitors (adverse effects), HIV Integrase Inhibitors (therapeutic use), HIV Protease Inhibitors (administration & dosage), HIV Protease Inhibitors (adverse effects), HIV Protease Inhibitors (therapeutic use), HIV-1, Humans, Lopinavir (administration & dosage), Lopinavir (adverse effects), Lopinavir (therapeutic use), Male, Raltegravir Potassium (administration & dosage), Raltegravir Potassium (adverse effects), Raltegravir Potassium (therapeutic use), Ritonavir (administration & dosage), Ritonavir (adverse effects), Ritonavir (therapeutic use), Secondary Care.
- MESH :
- chemical , administration & dosage : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- chemical , adverse effects : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- drug therapy : HIV Infections.
- chemical , therapeutic use : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- Adult, Drug Therapy, Combination, HIV-1, Humans, Male, Secondary Care.
Abstract
To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks.
Open label, centrally randomised trial.
Recruitment was from 37 primary and secondary care sites from Africa, Asia, Australia, Europe and Latin America.
541 HIV-1 infected adults virologically failing first-line non-NRTI + 2N(t)RTI, with no previous exposure to protease inhibitors or integrase strand transfer inhibitors were analysed, 425 completed 96 weeks follow up on randomised therapy.
Randomisation was 1:1 to Control or RAL.
Differences between the proportion of participants with plasma HIV-1 RNA (VL) <200 copies/mL by intention to treat were compared with a non-inferiority margin of −12%. Differences in biochemical, haematological and metabolic changes were assessed using T-tests.
VL <200 copies/mL at 96 weeks was: RAL 80.4%, Control 76.0% (difference: 4.4 [95%CI −2.6, 11.3]) and met non-inferiority criteria. The RAL arm had a significantly higher mean change (difference Control-RAL; 95%CI) in haemoglobin (−2.9; −5.7, −1.1), total lymphocytes (−0.2; −0.3, −0.0), total cholesterol (−0.5; −0.8, −0.3), HDL cholesterol (−0.1; −0.1, −0.0) and LDL cholesterol (−0.3; −0.5, −0.2).
At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles. These results support the use of a combination LPV/r and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs.
ClinicalTrials.gov
Url:
DOI: 10.1371/journal.pone.0118228
PubMed: 25723472
PubMed Central: 4344344
Affiliations:
- Afrique du Sud, Argentine, Australie, France, Inde, Thaïlande, États-Unis
- Illinois, Maryland, New Jersey, Nouvelle-Galles du Sud, Île-de-France
- Baltimore, Paris, Sydney
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000303
- to stream Pmc, to step Curation: 000303
- to stream Pmc, to step Checkpoint: 000D57
- to stream PubMed, to step Corpus: 002F98
- to stream PubMed, to step Curation: 002F17
- to stream PubMed, to step Checkpoint: 002F17
- to stream Ncbi, to step Merge: 002302
- to stream Ncbi, to step Curation: 002302
- to stream Ncbi, to step Checkpoint: 002302
- to stream Main, to step Merge: 002927
- to stream Main, to step Curation: 002927
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection</title>
<author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A." last="Boyd">Mark A. Boyd</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
<affiliation wicri:level="1"><nlm:aff id="aff002"><addr-line>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India</addr-line>
</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai</wicri:regionArea>
<wicri:noRegion>Chennai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L." last="Moore">Cecilia L. Moore</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Losso, Marcello H" sort="Losso, Marcello H" uniqKey="Losso M" first="Marcello H." last="Losso">Marcello H. Losso</name>
<affiliation wicri:level="1"><nlm:aff id="aff003"><addr-line>Hospital JM Ramos Mejia, Buenos Aires, Argentina</addr-line>
</nlm:aff>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Hospital JM Ramos Mejia, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nwizu, Chidi A" sort="Nwizu, Chidi A" uniqKey="Nwizu C" first="Chidi A." last="Nwizu">Chidi A. Nwizu</name>
<affiliation wicri:level="3"><nlm:aff id="aff004"><addr-line>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:regionArea>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
<affiliation wicri:level="1"><nlm:aff id="aff005"><addr-line>University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa</addr-line>
</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>University of the Witwatersrand and Baragwanath Hospital, Johannesburg</wicri:regionArea>
<wicri:noRegion>Johannesburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kerr, Stephen J" sort="Kerr, Stephen J" uniqKey="Kerr S" first="Stephen J." last="Kerr">Stephen J. Kerr</name>
<affiliation wicri:level="1"><nlm:aff id="aff006"><addr-line>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand</addr-line>
</nlm:aff>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sohn, Annette H" sort="Sohn, Annette H" uniqKey="Sohn A" first="Annette H." last="Sohn">Annette H. Sohn</name>
<affiliation wicri:level="1"><nlm:aff id="aff007"><addr-line>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand</addr-line>
</nlm:aff>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name>
<affiliation wicri:level="2"><nlm:aff id="aff008"><addr-line>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name>
<affiliation wicri:level="2"><nlm:aff id="aff009"><addr-line>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:aff id="aff010"><addr-line>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25723472</idno>
<idno type="pmc">4344344</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344</idno>
<idno type="RBID">PMC:4344344</idno>
<idno type="doi">10.1371/journal.pone.0118228</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000303</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000303</idno>
<idno type="wicri:Area/Pmc/Curation">000303</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000303</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000D57</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000D57</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002F98</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F98</idno>
<idno type="wicri:Area/PubMed/Curation">002F17</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F17</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F17</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F17</idno>
<idno type="wicri:Area/Ncbi/Merge">002302</idno>
<idno type="wicri:Area/Ncbi/Curation">002302</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002302</idno>
<idno type="wicri:Area/Main/Merge">002927</idno>
<idno type="wicri:Area/Main/Curation">002927</idno>
<idno type="wicri:Area/Main/Exploration">002927</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection</title>
<author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A." last="Boyd">Mark A. Boyd</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
<affiliation wicri:level="1"><nlm:aff id="aff002"><addr-line>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India</addr-line>
</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai</wicri:regionArea>
<wicri:noRegion>Chennai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L." last="Moore">Cecilia L. Moore</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Losso, Marcello H" sort="Losso, Marcello H" uniqKey="Losso M" first="Marcello H." last="Losso">Marcello H. Losso</name>
<affiliation wicri:level="1"><nlm:aff id="aff003"><addr-line>Hospital JM Ramos Mejia, Buenos Aires, Argentina</addr-line>
</nlm:aff>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Hospital JM Ramos Mejia, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nwizu, Chidi A" sort="Nwizu, Chidi A" uniqKey="Nwizu C" first="Chidi A." last="Nwizu">Chidi A. Nwizu</name>
<affiliation wicri:level="3"><nlm:aff id="aff004"><addr-line>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:regionArea>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
<affiliation wicri:level="1"><nlm:aff id="aff005"><addr-line>University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa</addr-line>
</nlm:aff>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>University of the Witwatersrand and Baragwanath Hospital, Johannesburg</wicri:regionArea>
<wicri:noRegion>Johannesburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kerr, Stephen J" sort="Kerr, Stephen J" uniqKey="Kerr S" first="Stephen J." last="Kerr">Stephen J. Kerr</name>
<affiliation wicri:level="1"><nlm:aff id="aff006"><addr-line>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand</addr-line>
</nlm:aff>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sohn, Annette H" sort="Sohn, Annette H" uniqKey="Sohn A" first="Annette H." last="Sohn">Annette H. Sohn</name>
<affiliation wicri:level="1"><nlm:aff id="aff007"><addr-line>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand</addr-line>
</nlm:aff>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name>
<affiliation wicri:level="2"><nlm:aff id="aff008"><addr-line>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name>
<affiliation wicri:level="2"><nlm:aff id="aff009"><addr-line>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:aff id="aff010"><addr-line>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name>
<affiliation wicri:level="3"><nlm:aff id="aff001"><addr-line>The Kirby Institute, UNSW Australia, Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Kirby Institute, UNSW Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PLoS ONE</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Integrase Inhibitors (administration & dosage)</term>
<term>HIV Integrase Inhibitors (adverse effects)</term>
<term>HIV Integrase Inhibitors (therapeutic use)</term>
<term>HIV Protease Inhibitors (administration & dosage)</term>
<term>HIV Protease Inhibitors (adverse effects)</term>
<term>HIV Protease Inhibitors (therapeutic use)</term>
<term>HIV-1</term>
<term>Humans</term>
<term>Lopinavir (administration & dosage)</term>
<term>Lopinavir (adverse effects)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Male</term>
<term>Raltegravir Potassium (administration & dosage)</term>
<term>Raltegravir Potassium (adverse effects)</term>
<term>Raltegravir Potassium (therapeutic use)</term>
<term>Ritonavir (administration & dosage)</term>
<term>Ritonavir (adverse effects)</term>
<term>Ritonavir (therapeutic use)</term>
<term>Secondary Care</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Humains</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Inhibiteurs de l'intégrase du VIH (administration et posologie)</term>
<term>Inhibiteurs de l'intégrase du VIH (effets indésirables)</term>
<term>Inhibiteurs de l'intégrase du VIH (usage thérapeutique)</term>
<term>Inhibiteurs de protéase du VIH (administration et posologie)</term>
<term>Inhibiteurs de protéase du VIH (effets indésirables)</term>
<term>Inhibiteurs de protéase du VIH (usage thérapeutique)</term>
<term>Lopinavir (administration et posologie)</term>
<term>Lopinavir (effets indésirables)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Mâle</term>
<term>Raltégravir de potassium (administration et posologie)</term>
<term>Raltégravir de potassium (effets indésirables)</term>
<term>Raltégravir de potassium (usage thérapeutique)</term>
<term>Ritonavir (administration et posologie)</term>
<term>Ritonavir (effets indésirables)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Soins secondaires</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>HIV Integrase Inhibitors</term>
<term>HIV Protease Inhibitors</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>HIV Integrase Inhibitors</term>
<term>HIV Protease Inhibitors</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de l'intégrase du VIH</term>
<term>Inhibiteurs de protéase du VIH</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de l'intégrase du VIH</term>
<term>Inhibiteurs de protéase du VIH</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>HIV Integrase Inhibitors</term>
<term>HIV Protease Inhibitors</term>
<term>Lopinavir</term>
<term>Raltegravir Potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'intégrase du VIH</term>
<term>Inhibiteurs de protéase du VIH</term>
<term>Lopinavir</term>
<term>Raltégravir de potassium</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>HIV-1</term>
<term>Humans</term>
<term>Male</term>
<term>Secondary Care</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Humains</term>
<term>Mâle</term>
<term>Soins secondaires</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="sec001"><title>Objective</title>
<p>To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks.</p>
</sec>
<sec id="sec002"><title>Design</title>
<p>Open label, centrally randomised trial.</p>
</sec>
<sec id="sec003"><title>Setting</title>
<p>Recruitment was from 37 primary and secondary care sites from Africa, Asia, Australia, Europe and Latin America.</p>
</sec>
<sec id="sec004"><title>Subjects</title>
<p>541 HIV-1 infected adults virologically failing first-line non-NRTI + 2N(t)RTI, with no previous exposure to protease inhibitors or integrase strand transfer inhibitors were analysed, 425 completed 96 weeks follow up on randomised therapy.</p>
</sec>
<sec id="sec005"><title>Intervention</title>
<p>Randomisation was 1:1 to Control or RAL.</p>
</sec>
<sec id="sec006"><title>Main outcome measures</title>
<p>Differences between the proportion of participants with plasma HIV-1 RNA (VL) <200 copies/mL by intention to treat were compared with a non-inferiority margin of −12%. Differences in biochemical, haematological and metabolic changes were assessed using T-tests.</p>
</sec>
<sec id="sec007"><title>Results</title>
<p>VL <200 copies/mL at 96 weeks was: RAL 80.4%, Control 76.0% (difference: 4.4 [95%CI −2.6, 11.3]) and met non-inferiority criteria. The RAL arm had a significantly higher mean change (difference Control-RAL; 95%CI) in haemoglobin (−2.9; −5.7, −1.1), total lymphocytes (−0.2; −0.3, −0.0), total cholesterol (−0.5; −0.8, −0.3), HDL cholesterol (−0.1; −0.1, −0.0) and LDL cholesterol (−0.3; −0.5, −0.2).</p>
</sec>
<sec id="sec008"><title>Conclusion</title>
<p>At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles. These results support the use of a combination LPV/r and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs.</p>
</sec>
<sec id="sec009"><title>Trial Registration</title>
<p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00931463">NCT00931463</ext-link>
</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Boyd, Ma" uniqKey="Boyd M">MA Boyd</name>
</author>
<author><name sortKey="Kumarasamy, N" uniqKey="Kumarasamy N">N Kumarasamy</name>
</author>
<author><name sortKey="Moore, Cl" uniqKey="Moore C">CL Moore</name>
</author>
<author><name sortKey="Nwizu, C" uniqKey="Nwizu C">C Nwizu</name>
</author>
<author><name sortKey="Losso, Mh" uniqKey="Losso M">MH Losso</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Paton, Ni" uniqKey="Paton N">NI Paton</name>
</author>
<author><name sortKey="Kityo, C" uniqKey="Kityo C">C Kityo</name>
</author>
<author><name sortKey="Hoppe, A" uniqKey="Hoppe A">A Hoppe</name>
</author>
<author><name sortKey="Reid, A" uniqKey="Reid A">A Reid</name>
</author>
<author><name sortKey="Kambugu, A" uniqKey="Kambugu A">A Kambugu</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Levey, As" uniqKey="Levey A">AS Levey</name>
</author>
<author><name sortKey="Bosch, Jp" uniqKey="Bosch J">JP Bosch</name>
</author>
<author><name sortKey="Lewis, Jb" uniqKey="Lewis J">JB Lewis</name>
</author>
<author><name sortKey="Greene, T" uniqKey="Greene T">T Greene</name>
</author>
<author><name sortKey="Rogers, N" uniqKey="Rogers N">N Rogers</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Chesney, Ma" uniqKey="Chesney M">MA Chesney</name>
</author>
<author><name sortKey="Ickovics, Jr" uniqKey="Ickovics J">JR Ickovics</name>
</author>
<author><name sortKey="Chambers, Db" uniqKey="Chambers D">DB Chambers</name>
</author>
<author><name sortKey="Gifford, Al" uniqKey="Gifford A">AL Gifford</name>
</author>
<author><name sortKey="Neidig, J" uniqKey="Neidig J">J Neidig</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lifson, Ar" uniqKey="Lifson A">AR Lifson</name>
</author>
<author><name sortKey="Belloso, Wh" uniqKey="Belloso W">WH Belloso</name>
</author>
<author><name sortKey="Davey, Rt" uniqKey="Davey R">RT Davey</name>
</author>
<author><name sortKey="Duprez, D" uniqKey="Duprez D">D Duprez</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="D Agostino, Rb" uniqKey="D Agostino R">RB D'Agostino</name>
</author>
<author><name sortKey="Grundy, S" uniqKey="Grundy S">S Grundy</name>
</author>
<author><name sortKey="Sullivan, Lm" uniqKey="Sullivan L">LM Sullivan</name>
</author>
<author><name sortKey="Wilson, P" uniqKey="Wilson P">P Wilson</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Wilson, Pw" uniqKey="Wilson P">PW Wilson</name>
</author>
<author><name sortKey="D Agostino, Rb" uniqKey="D Agostino R">RB D'Agostino</name>
</author>
<author><name sortKey="Parise, H" uniqKey="Parise H">H Parise</name>
</author>
<author><name sortKey="Sullivan, L" uniqKey="Sullivan L">L Sullivan</name>
</author>
<author><name sortKey="Meigs, Jb" uniqKey="Meigs J">JB Meigs</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Smith, F" uniqKey="Smith F">F Smith</name>
</author>
<author><name sortKey="Hammerstrom, T" uniqKey="Hammerstrom T">T Hammerstrom</name>
</author>
<author><name sortKey="Soon, G" uniqKey="Soon G">G Soon</name>
</author>
<author><name sortKey="Zhou, S" uniqKey="Zhou S">S Zhou</name>
</author>
<author><name sortKey="Chen, Bb" uniqKey="Chen B">BB Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Moyle, G" uniqKey="Moyle G">G Moyle</name>
</author>
<author><name sortKey="Sawyer, W" uniqKey="Sawyer W">W Sawyer</name>
</author>
<author><name sortKey="Law, M" uniqKey="Law M">M Law</name>
</author>
<author><name sortKey="Amin, J" uniqKey="Amin J">J Amin</name>
</author>
<author><name sortKey="Hill, A" uniqKey="Hill A">A Hill</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Goicoechea, M" uniqKey="Goicoechea M">M Goicoechea</name>
</author>
<author><name sortKey="Liu, S" uniqKey="Liu S">S Liu</name>
</author>
<author><name sortKey="Best, B" uniqKey="Best B">B Best</name>
</author>
<author><name sortKey="Sun, S" uniqKey="Sun S">S Sun</name>
</author>
<author><name sortKey="Jain, S" uniqKey="Jain S">S Jain</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Morlat, P" uniqKey="Morlat P">P Morlat</name>
</author>
<author><name sortKey="Vivot, A" uniqKey="Vivot A">A Vivot</name>
</author>
<author><name sortKey="Vandenhende, Ma" uniqKey="Vandenhende M">MA Vandenhende</name>
</author>
<author><name sortKey="Dauchy, Fa" uniqKey="Dauchy F">FA Dauchy</name>
</author>
<author><name sortKey="Asselineau, J" uniqKey="Asselineau J">J Asselineau</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Nishijima, T" uniqKey="Nishijima T">T Nishijima</name>
</author>
<author><name sortKey="Gatanaga, H" uniqKey="Gatanaga H">H Gatanaga</name>
</author>
<author><name sortKey="Shimbo, T" uniqKey="Shimbo T">T Shimbo</name>
</author>
<author><name sortKey="Komatsu, H" uniqKey="Komatsu H">H Komatsu</name>
</author>
<author><name sortKey="Endo, T" uniqKey="Endo T">T Endo</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Campo, R" uniqKey="Campo R">R Campo</name>
</author>
<author><name sortKey="Dejesus, E" uniqKey="Dejesus E">E DeJesus</name>
</author>
<author><name sortKey="Bredeek, Uf" uniqKey="Bredeek U">UF Bredeek</name>
</author>
<author><name sortKey="Henry, K" uniqKey="Henry K">K Henry</name>
</author>
<author><name sortKey="Khanlou, H" uniqKey="Khanlou H">H Khanlou</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Behrens, G" uniqKey="Behrens G">G Behrens</name>
</author>
<author><name sortKey="Maserati, R" uniqKey="Maserati R">R Maserati</name>
</author>
<author><name sortKey="Rieger, A" uniqKey="Rieger A">A Rieger</name>
</author>
<author><name sortKey="Domingo, P" uniqKey="Domingo P">P Domingo</name>
</author>
<author><name sortKey="Abel, F" uniqKey="Abel F">F Abel</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Gotuzzo, E" uniqKey="Gotuzzo E">E Gotuzzo</name>
</author>
<author><name sortKey="Markowitz, M" uniqKey="Markowitz M">M Markowitz</name>
</author>
<author><name sortKey="Ratanasuwan, W" uniqKey="Ratanasuwan W">W Ratanasuwan</name>
</author>
<author><name sortKey="Smith, G" uniqKey="Smith G">G Smith</name>
</author>
<author><name sortKey="Prada, G" uniqKey="Prada G">G Prada</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Reynes, J" uniqKey="Reynes J">J Reynes</name>
</author>
<author><name sortKey="Trinh, R" uniqKey="Trinh R">R Trinh</name>
</author>
<author><name sortKey="Pulido, F" uniqKey="Pulido F">F Pulido</name>
</author>
<author><name sortKey="Soto Malave, R" uniqKey="Soto Malave R">R Soto-Malave</name>
</author>
<author><name sortKey="Gathe, J" uniqKey="Gathe J">J Gathe</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Argentine</li>
<li>Australie</li>
<li>France</li>
<li>Inde</li>
<li>Thaïlande</li>
<li>États-Unis</li>
</country>
<region><li>Illinois</li>
<li>Maryland</li>
<li>New Jersey</li>
<li>Nouvelle-Galles du Sud</li>
<li>Île-de-France</li>
</region>
<settlement><li>Baltimore</li>
<li>Paris</li>
<li>Sydney</li>
</settlement>
</list>
<tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name>
</region>
<name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A." last="Boyd">Mark A. Boyd</name>
<name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name>
<name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name>
<name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L." last="Moore">Cecilia L. Moore</name>
</country>
<country name="Inde"><noRegion><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name>
</noRegion>
</country>
<country name="Argentine"><noRegion><name sortKey="Losso, Marcello H" sort="Losso, Marcello H" uniqKey="Losso M" first="Marcello H." last="Losso">Marcello H. Losso</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Nwizu, Chidi A" sort="Nwizu, Chidi A" uniqKey="Nwizu C" first="Chidi A." last="Nwizu">Chidi A. Nwizu</name>
</region>
<name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name>
<name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name>
</country>
<country name="Afrique du Sud"><noRegion><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name>
</noRegion>
</country>
<country name="Thaïlande"><noRegion><name sortKey="Kerr, Stephen J" sort="Kerr, Stephen J" uniqKey="Kerr S" first="Stephen J." last="Kerr">Stephen J. Kerr</name>
</noRegion>
<name sortKey="Sohn, Annette H" sort="Sohn, Annette H" uniqKey="Sohn A" first="Annette H." last="Sohn">Annette H. Sohn</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002927 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002927 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:4344344 |texte= Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25723472" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |